Heyman Richard A. 4

What Happened
Richard A. Heyman, a director of Enliven Therapeutics (ELVN), sold a total of 1,230 shares in open-market transactions on January 20, 2026. The sales were executed in two blocks: 512 shares at a weighted average price of $26.46 (proceeds $13,547) and 718 shares at a weighted average price of $26.96 (proceeds $19,354), for combined gross proceeds of approximately $32,901 (overall weighted avg ≈ $26.73 per share). These were outright sales (not buys or option exercises).

Key Details

• Transaction date: January 20, 2026; Form 4 filed January 22, 2026 (filed within the typical 2-business-day deadline).
• Shares sold: 512 @ $26.46 (≈ $13,547) and 718 @ $26.96 (≈ $19,354); total 1,230 shares for ≈ $32,901. Overall weighted average ≈ $26.73/share.
• Multiple trades: Sales were executed in multiple trades at price ranges of $25.7133–$26.7111 and $26.725–$27.3454; reported prices are weighted averages.
• Plan/ownership: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted Nov 15, 2024. Some shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust (Heyman Daigle Trust) and/or RAHD Capital LLC, for which Heyman is trustee/managing member.
• Shares owned after the transactions are not disclosed in the excerpt provided.

Context
Because these sales were made under a pre-established 10b5-1 trading plan, they were likely scheduled in advance and are generally considered routine rather than an immediate signal of the director’s view on the company. For retail investors, purchases typically carry more direct informational weight than scheduled sales; this filing is informational and factual, not a recommendation.